Published in J Pharm Sci on August 06, 2014
Pentanol and Benzyl Alcohol Attack Bacterial Surface Structures Differently. Appl Environ Microbiol (2015) 0.75
Determination and analysis of urea and guanidine hydrochloride denaturation curves. Methods Enzymol (1986) 12.22
Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature (2002) 10.81
Denaturant m values and heat capacity changes: relation to changes in accessible surface areas of protein unfolding. Protein Sci (1995) 9.23
Unfolding free energy changes determined by the linear extrapolation method. 1. Unfolding of phenylmethanesulfonyl alpha-chymotrypsin using different denaturants. Biochemistry (1988) 9.18
Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol (2005) 7.74
Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat Biotechnol (2004) 7.02
Ulp1-SUMO crystal structure and genetic analysis reveal conserved interactions and a regulatory element essential for cell growth in yeast. Mol Cell (2000) 6.39
Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature (2003) 4.98
Effects of protein aggregates: an immunologic perspective. AAPS J (2006) 4.74
3D domain swapping: as domains continue to swap. Protein Sci (2002) 4.35
Identifying the amylome, proteins capable of forming amyloid-like fibrils. Proc Natl Acad Sci U S A (2010) 3.50
AGGRESCAN: a server for the prediction and evaluation of "hot spots" of aggregation in polypeptides. BMC Bioinformatics (2007) 3.02
A test of the linear extrapolation of unfolding free energy changes over an extended denaturant concentration range. Biochemistry (1992) 2.73
Stability of protein pharmaceuticals: an update. Pharm Res (2010) 2.38
Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist (2001) 2.22
Induction and regulation of IFNs during viral infections. J Interferon Cytokine Res (2004) 2.19
Interferons and viral infections. Biofactors (2009) 1.99
The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carrier Syst (1993) 1.93
Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res (1997) 1.91
Cancer immunotherapy: the interferon-alpha experience. Semin Oncol (2002) 1.45
Aggregates in monoclonal antibody manufacturing processes. Biotechnol Bioeng (2011) 1.41
Prediction of "hot spots" of aggregation in disease-linked polypeptides. BMC Struct Biol (2005) 1.34
Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J Pharm Sci (2006) 1.32
Biophysical analysis of the interaction of human ifnar2 expressed in E. coli with IFNalpha2. J Mol Biol (1999) 1.31
New structural and functional aspects of the type I interferon-receptor interaction revealed by comprehensive mutational analysis of the binding interface. J Biol Chem (2000) 1.29
Mutational and structural analysis of the binding interface between type I interferons and their receptor Ifnar2. J Mol Biol (1999) 1.26
Antimicrobial preservative use in parenteral products: past and present. J Pharm Sci (2007) 1.25
Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci (2009) 1.23
The three-dimensional high resolution structure of human interferon alpha-2a determined by heteronuclear NMR spectroscopy in solution. J Mol Biol (1997) 1.20
Immunogenicity of aggregates of recombinant human growth hormone in mouse models. J Pharm Sci (2009) 1.10
Protein reconstitution and three-dimensional domain swapping: benefits and constraints of covalency. Protein Sci (2007) 1.08
Interleukin-1 receptor (IL-1R) liquid formulation development using differential scanning calorimetry. Pharm Res (1998) 1.03
Identification and characterization of protein folding intermediates. Biophys Chem (2007) 1.03
Cytochrome c polymerization by successive domain swapping at the C-terminal helix. Proc Natl Acad Sci U S A (2010) 1.01
Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers. Bioconjug Chem (2005) 1.00
Effects of pH, temperature, and sucrose on benzyl alcohol-induced aggregation of recombinant human granulocyte colony stimulating factor. J Pharm Sci (2006) 0.96
Mechanism for benzyl alcohol-induced aggregation of recombinant human interleukin-1 receptor antagonist in aqueous solution. J Pharm Sci (2004) 0.95
High-throughput biophysical analysis of protein therapeutics to examine interrelationships between aggregate formation and conformational stability. AAPS J (2013) 0.94
Persistent cutaneous insulin allergy resulting from high-molecular-weight insulin aggregates. Diabetes (1990) 0.92
Solvent denaturation of proteins and interpretations of the m value. Methods Enzymol (2009) 0.91
Benzyl alcohol-induced destabilization of interferon-gamma: a study by hydrogen-deuterium isotope exchange. J Pharm Sci (2004) 0.89
Clinical investigation of the immunogenicity of interferon-alpha 2a. J Interferon Cytokine Res (1997) 0.88
Interferon immunogenicity: technical evaluation of interferon-alpha 2a. J Interferon Cytokine Res (1997) 0.87
Temperature dependence of benzyl alcohol- and 8-anilinonaphthalene-1-sulfonate-induced aggregation of recombinant human interleukin-1 receptor antagonist. Biochemistry (2006) 0.86
Predicting accelerated aggregation rates for monoclonal antibody formulations, and challenges for low-temperature predictions. J Pharm Sci (2011) 0.85
Techniques for assessing the effects of pharmaceutical excipients on the aggregation of porcine growth hormone. Pharm Res (1993) 0.85
Role of partial protein unfolding in alcohol-induced protein aggregation. Proteins (2010) 0.85
Interferon-alpha in inflammation and immunity. Cell Mol Biol (Noisy-le-grand) (2001) 0.84
Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem (2005) 0.84
Mechanisms of m-cresol-induced protein aggregation studied using a model protein cytochrome c. J Pharm Sci (2011) 0.82
Effects of benzyl alcohol on aggregation of recombinant human interleukin-1-receptor antagonist in reconstituted lyophilized formulations. J Pharm Sci (2005) 0.82
Orthogonal high-throughput thermal scanning method for rank ordering protein formulations. AAPS PharmSciTech (2013) 0.81
Development of a multidose formulation for a humanized monoclonal antibody using experimental design techniques. AAPS PharmSci (2003) 0.80
Development and use of enzyme-linked immunosorbent assays (ELISA) for the detection of protein aggregates in interferon-alpha (IFN-alpha) formulations. Pharm Res (1997) 0.79
Effect of antimicrobial preservatives on partial protein unfolding and aggregation. J Pharm Sci (2012) 0.78
High yield soluble bacterial expression and streamlined purification of recombinant human interferon α-2a. Protein Expr Purif (2014) 0.78
A turbidimetric method to determine visual appearance of protein solutions. J Pharm Sci Technol (1994) 0.77
Missense mutations in dystrophin that trigger muscular dystrophy decrease protein stability and lead to cross-beta aggregates. Proc Natl Acad Sci U S A (2010) 1.01
Periodicity in residual dipolar couplings and nucleic acid structures. J Am Chem Soc (2004) 0.87
Role of partial protein unfolding in alcohol-induced protein aggregation. Proteins (2010) 0.85
The N-terminal actin-binding tandem calponin-homology (CH) domain of dystrophin is in a closed conformation in solution and when bound to F-actin. Biophys J (2012) 0.84
Expression and characterization of a four-alpha-helix bundle protein that binds the volatile general anesthetic halothane. Biomacromolecules (2005) 0.82
Mechanisms of m-cresol-induced protein aggregation studied using a model protein cytochrome c. J Pharm Sci (2011) 0.82
The C-terminal domain of the utrophin tandem calponin-homology domain appears to be thermodynamically and kinetically more stable than the full-length protein. Biochemistry (2014) 0.80
Thermodynamic stability, unfolding kinetics, and aggregation of the N-terminal actin-binding domains of utrophin and dystrophin. Proteins (2012) 0.79
Effect of antimicrobial preservatives on partial protein unfolding and aggregation. J Pharm Sci (2012) 0.78
Sevoflurane-induced structural changes in a four-alpha-helix bundle protein. Biochemistry (2005) 0.78
The actin binding affinity of the utrophin tandem calponin-homology domain is primarily determined by its N-terminal domain. Biochemistry (2014) 0.77
Controlled release of bioactive recombinant human growth hormone from PLGA microparticles. J Microencapsul (2010) 0.75